Coronavirus

The unanswered questions about antibody testing

This early, antibody testing for COVID-19 will not lead to quick and easy public policy decisions.

Governor Cuomo tours the Northwell Health Core Lab before announcing statewide antibody testing survey.

Governor Cuomo tours the Northwell Health Core Lab before announcing statewide antibody testing survey. Kevin P. Coughlin/Office of Governor Andrew M. Cuomo

On Sunday, Gov. Andrew Cuomo announced that the state would begin ramping up COVID-19 antibody testing, beginning with a random sampling of more than 3,000 New Yorkers. Viewed as a necessary step in the state’s fight against the coronavirus and eventually relaxing social distancing measures, antibody testing will help to fill in missing data about the scope of the virus’s spread in the state. But with many unknowns regarding how the virus acts and the accuracy and validity of new antibody tests, information gathered in this early stage will not provide any quick fixes or clear answers.

The antibody testing program should provide a rough estimate of how widespread COVID-19 infections are in New York and the severity of the state’s outbreak. As opposed to diagnostic tests, which tell whether a person currently has the virus, antibody tests can determine whether someone had the coronavirus in the past, regardless of whether they displayed symptoms or received a diagnosis. By using a large group of random people distributed across New York, the state can begin to figure out the true infection rate of COVID-19. Current data is based on diagnostic tests that generally are limited to people already suspected of having the disease. The random survey of antibody testing will provide a more representative pool of New Yorkers who may or may not have been eligible for a diagnostic test so far.

Public health experts have long been saying that because the United States has failed to get diagnostic testing up to scale, the number of cases that states report is likely far lower than the reality. A recent study in California found that about 4.1% of the population of Los Angeles County, or 221,000 to 442,000 people, had antibodies to the coronavirus by early April. This is far more than the 8,000 cases the county had reported at the time, and presents a better understanding of the virus’s spread and mortality rate, which may be lower than initial data has suggested. New York’s survey is expected to yield similar results in that it will reveal missing information that has resulted due to a lack of widespread testing.

Once analyzed, the results of the 3,000 random tests should give the state a much better idea about where the state stands as initial discussions begin about how and when to begin easing social distancing restrictions and restarting parts of the economy. Cuomo has repeatedly emphasized the need for widespread and comprehensive testing, both diagnostic and antibody, before that happens.

However, much is still unknown about the coronavirus and the body’s reaction to it, so if anyone is looking for immediate action as a result of antibody testing data, they ought not to, according to Cara Pager, an expert on viruses at the University at Albany. For example, although Cuomo has said the antibody test will show who has immunity, there is no public health consensus yet about whether someone who’s had the virus is now immune to it. Traditionally, a person infected with a virus gains at least short-term immunity through the production of antibodies. Numerous reports have emerged about people who tested positive for COVID-19 for a second time after they were believed to have recovered. It’s possible that the virus stayed in their body and never fully cleared, according to Columbia University assistant professor of epidemiology Matthew Lamb, but it’s still unclear exactly how the coronavirus acts. This would put a damper on trying to make sweeping claims about herd immunity, seen as one potential factor in reopening the economy, even if a large percentage of the population is found to have contracted the virus at some point.

Another unanswered question that could impact the idea of herd immunity is how many antibodies result in a sufficient level of immunity. The level of antibodies in the body provides a strong indicator about the level of immunity, as opposed to the knowledge that antibodies are simply present in the body. One test developed by Mount Sinai Laboratory Center for Clinical Laboratories in New York, which was recently approved by the U.S. Food and Drug Administration, would provide such information.

Yet another complicating factor is the lack of research that has been performed about those who have recovered from the coronavirus. A limited study out of China found that some recovered COVID-19 patients were found to have surprisingly low levels of antibodies, while others had no detectable antibodies at all. The data is still preliminary with a small sample size, but suggests the possibility that those who have been infected may still be at risk of reinfection.

The accuracy and reliability of tests is another potential roadblock to gathering information. Many tests available on the market now in the U.S., especially rapid tests that can be done quickly without much laboratory infrastructure, are flawed, at least in part because of the speed at which they were developed. The vast majority have not been approved by the FDA, but an easing of federal restrictions means they can still be sold and used. Only four antibody tests, including Mount Sinai’s, have received emergency approval.

Jonah Bruno, a spokesman for the state Department of Health, said two antibody tests were developed by the state at the Wadsworth Center public laboratory in Albany with “their rigorous standards.” He said the tests were approved by the state’s regulatory review program, which the FDA permitted as an alternate oversight path. Bruno said that one test has also been submitted for further approval by the FDA, with plans to also submit the second test.

People produce two different antibodies in response to an infection, but only one is what Pager calls a “neutralizing antibody” that actively kills a specific virus. Tests available on the market can test for both kinds of antibodies, or one or the other, but only the presence of the neutralizing antibody indicates the potential for long-term immunity. And while antibody tests are not used to determine whether someone is currently sick, it’s still possible that someone who tests positive for antibodies may still be fighting off the infection rather than having recovered from it. While this question is likely less relevant now, it still represents another complication that the state said it is prepared for. Bruno said that one test developed by the state is for the antibody that indicates potential immunity created as the virus begins to clear the body through a finger prick blood sample. The other uses blood drawn from a vein that detects total antibodies.

The expansion of antibody testing is a positive step for the state. The initial survey should provide much-needed information, which the state could use to develop policies. But that information is still preliminary and could be flawed as the world attempts to better understand the ongoing pandemic.

X
This website uses cookies to enhance user experience and to analyze performance and traffic on our website. We also share information about your use of our site with our social media, advertising and analytics partners. Learn More / Do Not Sell My Personal Information
Accept Cookies
X
Cookie Preferences Cookie List

Do Not Sell My Personal Information

When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about the First and Third Party Cookies used please follow this link.

Allow All Cookies

Manage Consent Preferences

Strictly Necessary Cookies - Always Active

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data, Targeting & Social Media Cookies

Under the California Consumer Privacy Act, you have the right to opt-out of the sale of your personal information to third parties. These cookies collect information for analytics and to personalize your experience with targeted ads. You may exercise your right to opt out of the sale of personal information by using this toggle switch. If you opt out we will not be able to offer you personalised ads and will not hand over your personal information to any third parties. Additionally, you may contact our legal department for further clarification about your rights as a California consumer by using this Exercise My Rights link

If you have enabled privacy controls on your browser (such as a plugin), we have to take that as a valid request to opt-out. Therefore we would not be able to track your activity through the web. This may affect our ability to personalize ads according to your preferences.

Targeting cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Social media cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools.

If you want to opt out of all of our lead reports and lists, please submit a privacy request at our Do Not Sell page.

Save Settings
Cookie Preferences Cookie List

Cookie List

A cookie is a small piece of data (text file) that a website – when visited by a user – asks your browser to store on your device in order to remember information about you, such as your language preference or login information. Those cookies are set by us and called first-party cookies. We also use third-party cookies – which are cookies from a domain different than the domain of the website you are visiting – for our advertising and marketing efforts. More specifically, we use cookies and other tracking technologies for the following purposes:

Strictly Necessary Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Functional Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Performance Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Social Media Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Targeting Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.